Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVOPHED vs ARAMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.
Treatment of hypotension in acute hypotensive states (e.g., septic shock, myocardial infarction, blood loss),Adjunct in the treatment of cardiac arrest (off-label)
Treatment of hypotension due to certain acute medical conditions (e.g., spinal anesthesia, drug-induced hypotension),Off-label: adjunct in the management of septic shock
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
Terminal elimination half-life is 2-4 hours. Clinical context: Requires continuous infusion for sustained blood pressure support.
Primarily metabolized in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Primarily hepatic via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT)
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Primarily renal: 85% unchanged drug in urine within 24 hours. Biliary/fecal: <5%.
Approximately 25-30% bound to albumin and other plasma proteins.
Approximately 50-70% bound to albumin and alpha-1 acid glycoprotein.
Approximately 0.7-1.0 L/kg. This indicates moderate distribution into tissues and plasma, consistent with a hydrophilic catecholamine.
0.5-1.0 L/kg. Clinical meaning: Indicates extensive distribution into tissues, consistent with a polar catecholamine.
Bioavailability is 100% via intravenous administration. Oral bioavailability is negligible due to extensive first-pass metabolism; not administered orally. Intramuscular or subcutaneous administration results in erratic absorption and significant vasoconstriction leading to poor bioavailability; thus, intravenous infusion is the only reliable route.
Intramuscular: 100%; Subcutaneous: 100%; Oral: negligible (<5%) due to extensive first-pass metabolism.
No specific dose adjustment required for renal impairment; titrate to clinical response.
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to reduced clearance.
No specific dose adjustment required for hepatic impairment; titrate to clinical response.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to altered metabolism.
Initial: 0.05-0.1 mcg/kg/min IV continuous infusion, titrate to effect; maximum dose not established.
Intravenous infusion: 0.1-0.2 mg/kg/dose, titrate to effect; maximum 0.5 mg/kg/dose.
Start at lower end of dosing range (2-4 mcg/min IV) due to increased sensitivity and comorbidities; titrate cautiously.
Use lower initial doses (e.g., 0.5-1 mg IV) and titrate slowly due to increased sensitivity and risk of hypertension.
No FDA boxed warning exists for LEVOPHED.
None
Risk of extravasation leading to tissue necrosis; ensure proper IV access and avoid infiltration,Monitor blood pressure, heart rate, and cardiac output continuously,May cause ischemia to limbs, kidneys, and splanchnic organs due to vasoconstriction,Use with caution in patients with hypertension, hyperthyroidism, or myocardial ischemia,Abrupt discontinuation may cause rebound hypotension
Risk of extravasation leading to tissue necrosis,Use with caution in patients with hypertension, hyperthyroidism, or cardiovascular disease,May cause bradycardia reflexively,Monitor blood pressure closely during administration
Hypersensitivity to norepinephrine or any component of the formulation,Hypovolemia (should be corrected before or during therapy),Use with cyclopropane or halothane anesthesia (increases risk of ventricular arrhythmias),Severe peripheral vascular disease with risk of gangrene
Hypersensitivity to metaraminol or any component,Use with MAO inhibitors (may cause severe hypertensive crisis),Use in patients with pheochromocytoma or severe hypertension
No clinically significant food interactions. Monitor for hyperglycemia in diabetic patients due to alpha-adrenergic effects.
Avoid tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) if taking MAOIs, but no specific dietary restrictions for metaraminol itself. Maintain adequate hydration as directed.
Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental blood flow due to maternal vasoconstriction may cause fetal hypoxia and bradycardia. Use only if clearly needed, and monitor fetal heart rate. FDA Pregnancy Category C.
FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities; no adequate human studies. Second/third trimester: Risk of maternal hypertension, reduced uterine blood flow; may cause fetal bradycardia, hypoxia, or metabolic acidosis. Avoid in eclampsia.
Norepinephrine is not expected to be excreted into breast milk in clinically significant amounts due to its short half-life and rapid metabolism. M/P ratio not established. Use with caution in breastfeeding women, as effects on the infant are unknown.
No human data. M/P ratio unknown. Excretion likely minimal due to high protein binding; exercise caution. Prefer alternative agents.
Pregnancy may alter the pharmacokinetics of norepinephrine, but specific dose adjustments are not established. Monitor maternal blood pressure closely and titrate to the lowest effective dose to maintain adequate uteroplacental perfusion. Starting dose is typically 0.5-1 mcg/min, titrated to effect.
Increased plasma volume may require higher initial doses. Titrate to effect; monitor for exaggerated pressor response. No fixed dose adjustment; individualize.
LEVOPHED (norepinephrine) is a first-line vasopressor for septic shock. Administer via central line to avoid extravasation injury; if extravasation occurs, treat with phentolamine 5-10 mg in 10 m L saline infiltrated locally. Titrate to mean arterial pressure (MAP) ≥ 65 mm Hg. Taper gradually to avoid rebound hypotension.
ARAMINE (metaraminol) is a potent vasopressor used primarily for acute hypotension. Monitor blood pressure frequently, ideally via intra-arterial line, as its duration of action is prolonged (up to 1 hour) and may cause rebound hypertension. Avoid extravasation; central line administration preferred. Tachyphylaxis can occur with prolonged use. It is contraindicated in patients with MAOI use within 14 days due to hypertensive crisis risk.
This medication is used to treat dangerously low blood pressure.,It will be given intravenously (IV) in a hospital setting by healthcare professionals.,You may feel anxiety, headache, or heart palpitations as the medication works.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the medication abruptly; it must be tapered under medical supervision.
This medication is given intravenously to raise blood pressure during emergencies.,You will be closely monitored with frequent blood pressure checks and possible arterial line.,Report any chest pain, severe headache, or blurred vision immediately.,Inform your healthcare provider of all medications you take, especially antidepressants.,Do not stop or change the dose without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVOPHED vs ARAMINE, answered by our medical review team.
LEVOPHED is a Vasopressor that works by Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.. ARAMINE is a Vasopressor that works by Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVOPHED and ARAMINE depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVOPHED is: Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.. The standard adult dose of ARAMINE is: Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVOPHED and ARAMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVOPHED is classified as Category C. Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental . ARAMINE is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities; no adequate human studies. Second/third trimester: Risk of maternal hypertension, reduced uterin. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.